US FDA Touts Big Improvements In Product Review Process: Report
Executive Summary
The US agency says it has either met or exceeded all its 2018-2020 strategic priorities, including simplifying core processes in its product review pathways.
You may also be interested in...
Regulatory And Commercial Should Be 'Hand In Hand' For Dx Success, Expert Says
Considering where and how a test will be used, and what kind of evidence regulators will want before clearing it, is key for developers of at home and point-of-care diagnostics.
US FDA’s Shuren: Device Center Will Roll Out New Strategic Priorities In 2022
Center for Devices and Radiological Health director Jeff Shuren said on 22 July that the center is incorporating lessons learned from the COVID-19 pandemic and its ongoing user-fee negotiations with industry into its upcoming set of strategic goals.
A Chat With Jeff Shuren: FDA Device Center Chief Worries About Agency Staffing; Talks MDUFA V, Pandemic, More
The head of the US agency’s device center spoke with Medtech Insight in an exclusive wide-ranging interview about his priorities for the future, the nuances of the MDUFA V user-fee negotiations, how COVID-19 has changed the agency, and more.